Substipharm is a privately held pharmaceutical Group.
They develop, supply and commercialize pharmaceuticals in more than 60 countries worldwide. Their portfolio of products comprises more than 40 different molecules. Their development pipeline includes as well more than 50 ongoing projects.
Their focus is on niche or differentiating products (based on technology and market size), as well as mature products for marketing authorizations that they have acquired from multinational companies.